Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Scorpius Holdings, Inc./ 8-K

Current Report · Items 5.02, 9.01 · 8-K

Scorpius Holdings, Inc.

SCPXOTCEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 29, 2026, William Ostrander, the Chief Financial Officer of Scorpius Holdings, Inc., a Delaware corporation (the “Company”), notified the Company of his decision to resign, effective March 31, 2026, from his position as the Company’s…

Filed Apr 8, 2026Accepted Apr 7, 2026, 5:43 PM EDTCIK 1476963Accession 0001553350-26-000055
View company →Permanent SEC source ↗
Share

Company context

We are a contract development and manufacturing organization (“CDMO”) that provides a comprehensive range of biologics manufacturing services from process development to Current Good Manufacturing Practices (“cGMP”) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. Scorpius pairs cGMP biomanufacturing and quality control expertise with cutting edge capabilities in immunoassays, molecular assays, and bioanalytical methods to support the production of cell- and gene-based therapies as well as large molecule biologics. Our services include clinical and commercial drug substance manufacturing, release and stability testing and variety of process development services, including upstream and downstream development and optimization, analytical method development, cell line development, testing and characterization. Our San Antonio, TX facility commenced operations in October 2022.

Current securities

SCPXOTC · EQUITY · Current
Historical securities (1)
SCPXDOTC · EQUITY · Historical · closed Aug 1, 2024

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsApr 24, 2026
  2. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesMar 19, 2026
  3. Completion of Acquisition or Disposition of Assets · Triggering Events That Accelerate or Increase a Direct Financial ObligationMar 10, 2026
  4. 10-Q filingFeb 17, 2026
  5. SCHEDULE 13G/A - filed by 3i, LP regarding Scorpius Holdings, Inc.Feb 5, 2026

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 29, 2026, William Ostrander, the Chief Financial Officer of Scorpius Holdings, Inc., a Delaware corporation (the “Company”), notified the Company of his decision to resign, effective March 31, 2026, from his position as the Company’s Chief Financial Officer. Mr. Ostrander did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.